Avenue Therapeutics Inc. (ATXI)
Market Open
12 Aug, 13:32
NASDAQ (CM) NASDAQ (CM) Primary $
0. 27
0
0%
$
990.14K Market Cap
- P/E Ratio
- Div Yield
20 Volume
-0.97 Eps
$ 0.27
Previous Close Want to track ATXI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ATXI trading today higher at $0.27, an increase of 0% from yesterday's close, completing a monthly decrease of -3.5714% or -$0.01. Over the past 12 months, ATXI stock lost -64%.
ATXI is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.07%, based on the last three reports.
Avenue Therapeutics Inc. has completed 2 stock splits, with the recent split occurring on Apr 26, 2024.
The company's stock is traded on one exchange.
Avenue Therapeutics Inc. (ATXI) FAQ
What is the stock price today?
The current price is $0.27.
On which exchange is it traded?
Avenue Therapeutics Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is ATXI.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 990.14K.
Has Avenue Therapeutics Inc. ever had a stock split?
Avenue Therapeutics Inc. had 2 splits and the recent split was on Apr 26, 2024.
Avenue Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alexandra MacLean CEO | NASDAQ (CM) Exchange | 05360L403 CUSIP |
| US Country | 1 Employees | - Last Dividend | 26 Apr 2024 Last Split | 27 Jun 2017 IPO Date |
Overview
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of treatments for rare and neurological diseases. Founded in 2015 and headquartered in Tampa, Florida, the company is committed to bringing innovative solutions to patients facing conditions with limited treatment options. Avenue Therapeutics is dedicated to advancing its portfolio through rigorous clinical trials aiming to address some of the most challenging conditions in the medical field today.
Products and Services
- AJ201: Currently in a Phase 1b/2a clinical trial, AJ201 is being developed for the treatment of spinal and bulbar muscular atrophy, a rare neuromuscular condition. Through its innovative mechanism, AJ201 aims to provide a significant advancement in the care and quality of life for patients suffering from this debilitating disease.
- Intravenous (IV) Tramadol: This product focus is on the management of post-operative acute pain, a common challenge faced by patients following surgical procedures. Through the use of IV Tramadol, Avenue Therapeutics is aiming to offer a more effective and safer alternative for pain management, which is crucial for the recovery and well-being of post-operative patients.
- BAER-101: Targeting the treatment of epilepsy and panic disorders, BAER-101 represents a promising advancement in the therapeutic options available for individuals living with these chronic conditions. By focusing on these neurological disorders, the company strives to provide new hope through innovative care solutions.
Contact Information
Address: 1111 Kane Concourse
Phone: 781 652 4500
Website: https://www.avenuetx.com
